Ketoscalp Tablet contains Ketoconazole 200 mg, an antifungal agent belonging to the imidazole class, indicated for the treatment of various fungal infections. Ketoconazole exerts its therapeutic effect by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting membrane integrity and leading to fungal cell death. Ketoscalp Tablet is primarily prescribed for systemic and superficial mycoses, including dermatophytosis, candidiasis, and seborrheic dermatitis caused by Malassezia species. It is also effective against pityriasis versicolor and other fungal infections resistant to topical therapy. The recommended dosage and duration of treatment depend on the specific infection and patient response, with careful monitoring advised to minimize potential adverse effects. Common side effects may include gastrointestinal disturbances such as nausea, vomiting, and abdominal pain, as well as rare hepatotoxicity; liver function tests should be monitored during prolonged therapy. Ketoscalp Tablet should be used cautiously in patients with pre-existing liver conditions or those taking medications metabolized by the cytochrome P450 system due to potential drug interactions. It is contraindicated in patients with hypersensitivity to ketoconazole or other azole antifungals. Ketoscalp Tablet offers an effective oral antifungal option for managing resistant or extensive fungal infections under medical supervision.